Reference : Ibandronate in profile: drug characteristics and clinical efficacy.
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/20323
Ibandronate in profile: drug characteristics and clinical efficacy.
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Neuprez, Audrey [Université de Liège - ULG > Département des sciences de la santé publique > Epidémiologie et santé publique > >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique >]
2008
Expert Opinion on Drug Metabolism & Toxicology
4
7
941-51
Yes (verified by ORBi)
International
1742-5255
[en] Aged ; Bone Density Conservation Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use ; Diphosphonates/adverse effects/pharmacokinetics/pharmacology/therapeutic use ; Female ; Humans ; Middle Aged ; Osteoporosis, Postmenopausal/prevention & control
[en] BACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice. OBJECTIVE: To review the profile of ibandronate, a monthly oral (150 mg) or quarterly intravenous injection (3 mg) of bisphosphonate. METHODS: The literature search was limited to publications of ibandronate data. RESULTS/CONCLUSION: Ibandronate is rapidly absorbed and distributed in the bone; it is not metabolised and is excreted in urine. Clinical trial data have demonstrated the efficacy of ibandronate in reducing fracture risk, increasing bone mineral density and reducing bone turnover. These data are supported by recent meta-analyses and a large database study that have demonstrated antifracture efficacy with the ibandronate regimens used in clinical practice. Overall, ibandronate has generally been well tolerated. Therefore, ibandronate is a useful treatment for postmenopausal osteoporosis.
http://hdl.handle.net/2268/20323
10.1517/17425255.4.7.941

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Ibandronate in profile - drug characteristics and clinical efficacy_ Expert Opinion 2008_JYR AN OB.pdfPublisher postprint890.26 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.